TNDM vs LMRI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TNDM · Tandem Diabetes Care$16.91 ▼ 6.00%
LMRI · Lumexa Imaging$13.43 ▲ 1.67%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TNDM -19.4%
- LMRI -27.5%
Head to head
| Metric | TNDM | LMRI |
|---|---|---|
| Price | $16.91 | $13.43 |
| Change today | ▼ 6.00% | ▲ 1.67% |
| Market cap | $1.18B | $1.29B |
| Return, 3 months | -25.9% | +14.4% |
| Return, year to date | -23.1% | -27.4% |
| Return, 1 year | +4.0% | – |
| P/E (TTM) | – | – |
| P/B | 8.7 | 2.1 |
| P/E percentile vs own 5y | 20th | 16th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5.8% | +5.1% |
| Net profit growth (YoY) | +59.6% | +138.0% |
| Gross margin | 56.0% | 14.9% |
| Operating margin | -4.4% | 1.4% |
| Net margin | -6.1% | -2.7% |
| Return on equity | -48.0% | -4.5% |
| Analyst target vs. price | +65.6% | +27.8% |
| Analyst buy share | 58% | 100% |
| RSI (14) | 45 | 76 |
| 30-day volatility | 55.5% | 53.4% |
| Max drawdown, 1 year | -54.6% | -63.5% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LMRI is the largest of the group by market value.
- TNDM is growing revenue fastest.
- LMRI keeps the most profit per dollar of sales.
- LMRI has been the calmest stock over the last 30 days.